IP Library Granted Patent US 6,852,757
Granted Patent B2
US 6,852,757 · App. 10/804,981 · Granted Feb 8, 2005

Isomer enriched conjugated linoleic acid compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,852,757
App. No.
10/804,981
Granted
Feb 8, 2005
Kind
B2
Abstract

Compositions and methods of using conjugated linoleic acid preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of conjugated linoleic acid containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.

Claims (14)

1. A method of alleviating the effects of viral infection comprising:

a) providing a patient suffering from a viral infection and a composition comprising t10,c12 CLA and c9,t11 CLA in a ratio of about 1.2:1 to 3:1; and

b) administering said composition to said patient.

2. The method of claim 1 , wherein said CLA composition is administered orally.

3. The method of claim 1 , wherein said CLA composition comprises free fatty acids of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

4. The method of claim 1 , wherein said CLA composition comprises esters of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

5. The method of claim 1 , wherein said CLA composition comprises acylglycerides of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

6. A method of alleviating the effects of administration of a vaccine comprising:

a) providing a patient to which a vaccine has been administered and a composition comprising t10,c12 CLA and c9,t11 CLA in a ratio of about 1.2:1 to 3:1; and

b) administering said composition to said patient.

7. The method of claim 6 , wherein said CLA composition is administered orally.

8. The method of claim 6 , wherein said CLA composition comprises free fatty acids of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

9. The method of claim 6 , wherein said CLA composition comprises esters of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

10. The method of claim 6 , wherein said CLA composition comprises acylglycerides of t10,c12 octadecadienoic acid and c9,t11 octadecadienoic acid.

Assignments (3)
CHANGE OF NAME Recorded Sep 7, 2007
From: NATURAL ASA
To: AKER BIOMARINE ASA
Reel/Frame 019805/0274 →
CHANGE OF NAME Recorded Sep 7, 2007
From: NATURAL ASA
To: AKER BIOMARINE ASA
Reel/Frame 019805/0418 →
RE-RECORD TO CORRECT THE ADDRESS OF THE ASSIGNEE. Recorded Feb 3, 2006
From: NATURAL CORPORATION
To: NATURAL ASA
Reel/Frame 017240/0646 →